Loading...
NPI 1518070879 · Yakima, WA · Ambulatory Surgical Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ehlers Eye Surgery LLC is a ambulatory surgical clinic/center provider located in Yakima, Washington. This profile covers 10 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Ehlers Eye Surgery LLC |
| Address | 3403 Powerhouse Rd |
| City | Yakima |
| State | WA |
| ZIP | 98902 |
| Taxonomy | Ambulatory Surgical Clinic/Center |
| NPI Enumerated | August 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $190.6K |
EHLERS EYE SURGERY LLC is registered as an Ambulatory Surgical Clinic/Center and its code mix is consistent with a combined cataract surgery and retinal injection practice: high-revenue surgical code 66984 (cataract extraction with IOL) and frequent intravitreal injection codes J0178 (aflibercept) and 67028 (injection into vitreous) dominate billing activity. This blend of procedural and drug-injection codes suggests the site operates both scheduled surgical cataract service lines and a recurring injection clinic for retinal disease management.
Medicare revenue is concentrated: total Medicare revenue is $2.1M and the providers top 3 Medicare codes account for 85.2% of that revenue. The leading Medicare contributors are J0178 ($986.7K revenue, 47.3%), 66984 ($686.4K revenue, 32.9%), and 67028 ($104.3K revenue, 5.0%), indicating most Medicare dollars flow from aflibercept administration and cataract surgery.
Medicaid billing is even more tightly concentrated: total Medicaid revenue is $190.6K and the top 3 Medicaid codes account for 99.6% of Medicaid revenue. The primary Medicaid drivers are 67028 ($112.1K revenue, 59.0%), 66984 ($70.8K revenue, 37.2%), and J9035 ($6.3K revenue, 3.3%), showing Medicaid receipts are overwhelmingly tied to intravitreal injections and cataract procedures.
Payer mix is Medicare-dominant by scale: Medicare revenue ($2.1M) substantially exceeds Medicaid revenue ($190.6K), so commercial/Medicare strategy and reimbursement changes will have a much larger impact on overall revenue than shifts in Medicaid. Although both payers are active, Medicare is the financial primary for this practice.
Competitive standing varies by service and payer: for Medicare, J0178 ranks #873 of 3204 providers (73rd percentile, characterized as typical/unremarkable national volume), 66984 ranks #2197 of 15965 providers (86th percentile, typical/unremarkable), while 67028 ranks #207 of 4255 providers (95th percentile, labeled notably above typical national volume). Those percentiles indicate the practice is a modest-to-strong national participant in retinal injections and a solid regional provider of cataract surgery, with injection volume particularly elevated.
In the state Medicaid market the provider is a mid-tier participant rather than a statewide dominant center: 67028 ranks #17 of 57 providers in-state (71st percentile, typical), 66984 ranks #14 of 51 (74th percentile, typical), and J9035 ranks #8 of 33 (78th percentile, typical). These in-state positions suggest consistent participation across key ophthalmology services but not market leadership.
Reimbursement and drug-mix dynamics shape revenue: on Medicare J0178 carries a relatively high avg paid/claim ($690) and produces the single-largest Medicare revenue line ($986.7K), whereas J9035 (bevacizumab) appears at high claim counts but much lower avg paid/claim ($54 Medicare, $4 Medicaid) and lower revenue share. This contrast shows that choice of anti-VEGF agent materially affects revenue per encounter even when injection volumes are high.
The practice has established tenure with an NPI enumeration date of 2006-08-17 (~20 years ago), indicating long-standing operations. Combined with the high concentration of revenue in the top 3 codes (85.2% Medicare; 99.6% Medicaid), this longevity plus narrow service dependence suggests steady specialization but also exposure if reimbursement or clinical mix shifts for those few high-impact codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,430 | $690 | $986.7K |
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 820 | $830 | $686.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,430 | $40 | $104.3K |
| J9035 | Injection, bevacizumab, 10 mg | 1,600 | $50 | $86.6K |
| J2778 | Injection, ranibizumab, 0.1 mg | 470 | $180 | $83.7K |
| 66821 | The provider removes the haziness from the capsule of the eye using a laser for a patient with a secondary membranous cataract. | 270 | $200 | $53.7K |
| 66982 | The provider inserts an intraocular lens prosthesis after extracapsular cataract extraction using complex techniques and devices. He may perform this by means of an iris expansion device, providing… | 60 | $820 | $46.6K |
| 15823 | In this procedure, the provider surgically trims excessive skin that weighs down the upper eyelid, typically to improve the cosmetic appearance of the face and due to the interference of the tissue… | 50 | $500 | $27.1K |
| 67917 | During this procedure, the provider performs an extensive repair of an ectropion, which is an outward turning of the lower eyelid and eyelashes, which can lead to excessive tearing and irritation of… | 20 | $590 | $9.4K |
| 65855 | In this procedure, the provider uses a laser to burn the trabecular meshwork, the tissue of mesh where the iris meets the sclera, to drain aqueous humor from the anterior chamber and treat glaucoma. | 20 | $100 | $2.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,440 | $50 | $112.1K |
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 860 | $80 | $70.8K |
| J9035 | Injection, bevacizumab, 10 mg | 1,580 | $1 | $6.3K |
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 80 | $10 | $830 |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer… | 920 | $0 | $0 |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | 920 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J9035 | Injection, bevacizumab, 10 mg | 8 | 30 | 420 | $190 | $160.8K |
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 14 | 50 | 410 | $180 | $154K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 17 | 60 | 710 | $40 | $81.7K |
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 544 | 710 | 480 | $10 | $16K |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer… | 5 | 50 | 90 | $1 | $1 |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | 3 | 30 | 120 | $0 | $0 |
Other providers in the same ZIP code as Ehlers Eye Surgery LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.